NCT07414056 Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation
| NCT ID | NCT07414056 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ain Shams University |
| Condition | Acute Respiratory Distress Syndrome (ARDS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-11-10 |
| Primary Completion | 2027-05-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-11-10 with a primary completion date of 2027-05-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the role of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as predictors for development of ARDS in pediatric burn patients.
Eligibility Criteria
Inclusion Criteria: * Age 1-12 years. * Patients presenting within 24 hours of burn injury. * Patients presenting with severe burns 20-40% of total body surface area (TBSA). * Thermal burns or scalds. * Both sexes. Exclusion Criteria: * Patient refusal to participate in the trial. * Age \<1 \& \>12 years. * Delayed admission \>24h post-injury. * Patients presenting with burns \<20% or \>40% of TBSA. * Non-thermal burns. * Associated medical comorbidities: Chronic liver or kidney diseases, anemia. * Preexisting chronic lung disease (e.g., cystic fibrosis, severe bronchopulmonary dysplasia). * Inflammatory conditions (e.g., inflammatory bowel disease). * Immunocompromised individuals, autoimmune diseases, those undergoing treatment with immunosuppressants, corticosteroids, cytotoxic chemotherapy. * Known malignancies, hematologic malignancy or conditions altering WBC/platelets significantly. * Previous malnutrition. * Immunosuppressive therapy prior to admission (e.g., chronic steroids).
Frequently Asked Questions
Who can join the NCT07414056 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 12 Years, studying Acute Respiratory Distress Syndrome (ARDS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07414056 currently recruiting?
Yes, NCT07414056 is actively recruiting participants. Visit ClinicalTrials.gov or contact Ain Shams University to inquire about joining.
Where is the NCT07414056 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07414056 clinical trial?
NCT07414056 is sponsored by Ain Shams University. The trial plans to enroll 60 participants.